Products
Platform
Research
Market
Learn
Compare Mutual Funds
Fund Comparison
Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Select a Mutual Fund
Fund Details
Risk | Very High | - |
Rating | - | - |
Min SIP Amount | ₹1000 | - |
Expense Ratio | 2.37 | - |
NAV | ₹9.97 | - |
Fund Started | 19 Nov 2024 | - |
Fund Size | ₹106.92 Cr | - |
Exit Load | Exit load of 0.50%, if redeemed within 90 days. | - |
Risk
Very High
-
Rating
-
-
Min SIP Amount
₹1000
-
Expense Ratio
2.37
-
NAV
₹9.97
-
Fund Started
19 Nov 2024
-
Fund Size
₹106.92 Cr
-
Exit Load
Exit load of 0.50%, if redeemed within 90 days.
-
Returns
1 Year | - | - |
3 Year | - | - |
5 Year | - | - |
1 Year
-
-
3 Year
-
-
5 Year
-
-
Holding Analysis
Equity | 97.50% | - |
Cash | 1.02% | - |
Equity
97.50%
-
Cash
1.02%
-
Top Holdings
Top 10 Holdings |
| - |
Top 10 Holdings
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 10.89% |
Divi's Laboratories Ltd. | 9.82% |
Max Healthcare Institute Ltd. | 7.10% |
Aster DM Healthcare Ltd. | 6.35% |
Dr. Reddy's Laboratories Ltd. | 5.53% |
Mankind Pharma Ltd. | 4.76% |
JB Chemicals & Pharmaceuticals Ltd. | 4.53% |
Rubicon Research Ltd. | 3.87% |
Krishna Institute of Medical Sciences Ltd | 3.69% |
Ajanta Pharma Ltd. | 3.52% |
-
Fund Manager
Name | Vivek Sharma | - |
Start Date | 11 Nov 2025 | - |
Name
Vivek Sharma
-
Start Date
11 Nov 2025
-
About Fund
Description | The scheme seek to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies. | - |
Launch Date | 19 Nov 2024 | - |
Description
The scheme seek to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies.
-
Launch Date
19 Nov 2024
-